Clinical Trials Logo

Hantavirus Infections clinical trials

View clinical trials related to Hantavirus Infections.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05415904 Active, not recruiting - Clinical trials for Hantavirus Nephropathy

Hantavirus Nephropathy in North-Eastern France : Severity Risk Factors and Prognostic Tools

HANTA-NE
Start date: May 20, 2022
Phase:
Study type: Observational

Hantaviruses are emerging pathogens responsible for hemorrhagic fever with renal syndrome. Severity risks factors aren't consensual in litterature, mostly related to scandinavian cohorts. A prognostic score was created to help patient's orientation in healthcare system but wasn't independantly validated (Hentzien, Emerging infectious diseases 2018). This retrospective cohort of hantavirus infected hospitalized adults patients in the north-eastern quarter of France between 2013 and 2022 will specify the kidney damage during infection and risk factors for a severe form (defined par acute kidney injury KDIGO 3). The previous prognostic score performance will be evaluated in this cohort.

NCT ID: NCT03718130 Active, not recruiting - Clinical trials for Hantaan Virus Disease, Puumala Virus

Combination HTNV and PUUV DNA Vaccine

Start date: October 11, 2019
Phase: Phase 1
Study type: Interventional

To evaluate the safety and reactogenicity of the hantaan virus (HTNV), puumala virus (PUUV), and combination HTNV/PUUV DNA vaccine candidates delivered to healthy adults